Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 22, 2025
Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.
Journal: Annual review of pharmacology and toxicology
Published: August 19, 2025
Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.
Journal: American journal of clinical oncology
Published: July 11, 2025
From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.
Journal: Molecular diagnosis & therapy
Published: July 08, 2025
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: June 02, 2025
Pharmacologic management of HR+/HER2- mBC: a clinically oriented review.
Journal: Frontiers in oncology
Published: March 19, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2025
KRAS codon-specific mutations differentially toggle PI3K pathway signaling and alter sensitivity to inavolisib (GDC-0077).
Journal: Molecular cancer therapeutics
Published: February 18, 2025
Structure-Property Relationships Reported for the New Drugs Approved in 2024.
Journal: Mini reviews in medicinal chemistry
Published: February 03, 2025
Inavolisib Therapy in Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: January 15, 2025
Inavolisib Therapy in Advanced Breast Cancer. Reply.
Journal: The New England journal of medicine
Published: January 15, 2025
Inavolisib.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: December 24, 2024
Last Updated: 10/31/2025